Drug intelligence / Profile preview

MK-1942

Development stage: Discontinued
Lead developer: Merck
Modality: Small Molecules
Administration: Oral

Overview

MK-1942 is an investigational small molecule drug developed by Merck Sharp & Dohme for the treatment of Alzheimer's disease and treatment-resistant depression. It was administered orally in capsule form and studied as an adjunct therapy for mild to moderate Alzheimer's disease dementia, as well as an add-on therapy for major depressive disorder that had not responded to other antidepressants. The exact mechanism of action remains undefined, but it was intended to complement existing treatments in both indications. Development was discontinued after Phase II trials were terminated due to concerns about potential liver toxicity observed during clinical studies[1][3][4][7].

Other names: MK 1942MK1942MK-1942

Targets

GRM2 (mGluR2)

Beyond the preview

Go deeper on MK-1942.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on MK-1942.

Explore the full profile